ABVC BioPharma, Inc. (ABVC)
NASDAQ: ABVC · Real-Time Price · USD
1.340
-0.070 (-4.96%)
Mar 6, 2026, 4:00 PM EST - Market closed
ABVC BioPharma Employees
As of December 31, 2024, ABVC BioPharma had 19 total employees, including 16 full-time and 3 part-time employees. The number of employees did not change compared to the previous year.
Employees
19
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$416,240
Market Cap
33.09M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Celularity | 123 |
| Lisata Therapeutics | 26 |
| INmune Bio | 22 |
| AN2 Therapeutics | 22 |
| Edesa Biotech | 17 |
| Outlook Therapeutics | 17 |
| CervoMed | 15 |
ABVC News
- 1 year ago - ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners - GlobeNewsWire
- 1 year ago - ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners - GlobeNewsWire
- 1 year ago - ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements - GlobeNewsWire
- 2 years ago - AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share - GlobeNewsWire
- 2 years ago - ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M - GlobeNewsWire
- 2 years ago - ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M - GlobeNewsWire
- 2 years ago - ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M - GlobeNewsWire
- 2 years ago - ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine - GlobeNewsWire